Trade

with

Perrigo Co PLC
(NYSE: PRGO)
AdChoices
155.15
+1.24
+0.81%
After Hours :
155.15
0.00
0.00%

Open

154.97

Previous Close

153.91

Volume (Avg)

464.51k (888.60k)

Day's Range

153.40-155.49

52Wk Range

125.37-168.39

Market Cap.

20.76B

Dividend Rate (Yield )

0.42 (0.26%)

Beta

0.29

Shares Outstanding

133.93M

P/E Ratio (EPS)

87.72 (1.77)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 4.06B

    • Net Income

    • 205.30M

    • Market Cap.

    • 20.76B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 5.06

    • PEG (Price/Earnings Growth) Ratio

    • 1.41

    • Beta

    • 0.29

    • Forward P/E

    • 20.49

    • Price/Sales

    • 4.42

    • Price/Book Value

    • 2.39

    • Price/Cash flow

    • 25.84

      • EBITDA

      • 925.90M

      • Return on Capital %

      • 2.14

      • Return on Equity %

      • 3.72

      • Return on Assets %

      • 2.14

      • Book Value/Share

      • 64.96

      • Shares Outstanding

      • 133.93M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.11 (8/27/2014)

      • Dividend Declaration Date

      • 8/13/2014

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 180.50

        • Credit Rating

        • BBB+

        • Analysts

        • 6

        • EPS Estimate

        • 4.42

        • Cashflow Estimate

        • 8.50

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 18.30

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -53.50

          • -26.33

          • Net Income

            Q/Q (last year)

          • 11.40

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 15.14

          • -5.42

          • Net Income

            5-Year Annual Average

          • 7.80

          • 3.16

          • Dividends

            5-Year Annual Average

          • 12.65

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 35.65

            • 64.72

            • Pre-Tax Margin

            • 6.71

            • 13.77

            • Net Profit Margin

            • 5.06

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 34.70

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 14.00

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • 10.50

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.36

              • 0.33

              • Current Ratio

              • 2.37

              • 1.52

              • Quick Ratio

              • 1.62

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.60

              • 1.91

              • Book Value/Share

              • 64.96

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 87.72

                • 65.79

                • P/E Ratio 5-Year High

                • 95.14

                • 237.47

                • P/E Ratio 5-Year Low

                • 20.30

                • 19.71

                • Price/Sales Ratio

                • 4.42

                • 3.69

                • Price/Book Value

                • 2.39

                • 3.46

                • Price/Cash Flow Ratio

                • 25.84

                • 22.12

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • 22.03

                    • Dividend Date

                    • 8/13/2014

                    • Ex-Dividend Date

                    • 8/27/2014

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • 3.72

                        (19.30)

                      • 7.86

                        (9.58)

                      • Return on Assets %

                        (5-Year Average)

                      • 2.14

                        (8.30)

                      • 4.14

                        (5.54)

                      • Return on Capital %

                        (5-Year Average)

                      • 2.53

                        (11.40)

                      • 5.59

                        (7.66)

                      • Income/Employee

                      • 20.09k

                      • 27.79k

                      • Inventory Turnover

                      • 3.91

                      • 1.80

                      • Asset Turnover

                      • 0.42

                      • 0.38

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      567.00M
                      Operating Margin
                      13.96
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      25.84
                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Specific & Generic

                      Type

                      Aggressive Growth

                      Style

                      Large Growth

                      Perrigo Co PLC was incorporated under the laws of Ireland on June 28, 2013. The Company develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ...moreingredients. The Company is a manufacturer of OTC healthcare products for the store brand market. The Company has five reportable segments, aligned primarily by type of product: Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, and Specialty Sciences. The Consumer Healthcare segment is the store brand manufacturer of OTC pharmaceutical products. Its product categories include analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation and animal health; secondary product categories include feminine hygiene, diabetes care and dermatological care. T...morehe Nutritionals segment develops, manufactures, markets and distributes store brand infant and toddler formula products, infant and toddler foods, and vitamin, mineral and dietary supplement products to retailers, distributors and consumers primarily in the U.S., Canada, Mexico and China. The Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of generic prescription drugs primarily for the U.S. market. it encompasses an array of topical dosage forms such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions and powders. The Company develops, manufactures, and markets API used worldwide by the generic drug industry and branded pharmaceutical companies. Certain of these ingredients are used in its own pharmaceutical products. The manufacturing of these API occurs primarily in Israel. As a result of the Elan acquisition on December 18, 2013, the Company expanded its operating segments to include the Specialty Sciences segment, which is comprised primarily of assets focused on the treatment of Multiple Sclerosis (Tysabri®). Its competitors in the U.S. Consumer Healthcare market are Dr. Reddy’s Laboratories, Ltd., Actavis Inc., Ranbaxy Inc., PL Developments, Nipro Corporation, and LNK International, Inc. Abbott Laboratories, Mead Johnson Nutrition Co., Nestle S.A. (Gerber) and Danone Baby Nutrition. Tysabri® competes primarily with Avonex, marketed by Biogen Idec; Betaseron®, marketed by Berlex (an affiliate of Bayer Schering Pharma AG) in the U.S. The Company is subject to various environmental laws and regulations.lessless

                      Key People

                      Mr. Joseph C. Papa

                      CEO/President/Chairman of the Board/Director

                      Ms. Judy L. Brown

                      CFO/Chief Accounting Officer/Executive VP

                      Mr. Thomas M. Farrington

                      Senior VP/Chief Information Officer

                      Mr. John T. Hendrickson

                      Executive VP, Divisional

                      Mr. Jeffrey R. Needham

                      Executive VP/General Manager, Divisional

                      • Perrigo Co PLC

                      • Lower Grand Canal Street

                      • Dublin, 49010

                      • IRL.Map

                      • Phone: +353 17094002

                      • Fax: -

                      • perrigo.com

                      Incorporated

                      2013

                      Employees

                      10,220